Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Lees

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|October 1, 2011
Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in SwedenLars Ryttberg, Alex Diamantopoulos, Fiona Forster, et al.
Journal of Medical Economics|March 10, 2011
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacementCorinne Lereun, Phillip Wells, Alex Diamantopoulos, et al.
Pharmacoeconomics|December 23, 2011
Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspectiveAurea Duran, Nishan Sengupta, Alexander Diamantopoulos, et al.
Thrombosis and Haemostasis|September 1, 2010
Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in CanadaAlexander Diamantopoulos, Michael Lees, Philip S Wells, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 21, 2004
Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UKMike Aristides, Michael Lees, Nick Botwood, et al.
Autophagy|December 11, 2012
IFNB1/interferon-β-induced autophagy in MCF-7 breast cancer cells counteracts its proapoptotic functionMalene Ambjørn, Patrick Ejlerskov, Yawei Liu, et al.
Journal of Medical Economics|April 13, 2012
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health PerspectiveHeather McDonald, Alex Diamantopoulos, Philip Wells, et al.
Health and Quality of Life Outcomes|December 2, 2008
Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitationAndrew Briggs, Diane Wild, Michael Lees, et al.
Lung Cancer (Amsterdam, Netherlands)|December 31, 2003
Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in EuropeJoan Schiller, Dominic Tilden, Michael Aristides, et al.
Population Health Metrics|November 28, 2018
The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictionsDavid Campbell, Ken O'Day, Nadine Hertel, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Expert Review of Pharmacoeconomics & Outcomes Research|October 1, 2011
Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in SwedenLars Ryttberg, Alex Diamantopoulos, Fiona Forster, et al.
Journal of Medical Economics|March 10, 2011
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacementCorinne Lereun, Phillip Wells, Alex Diamantopoulos, et al.
Pharmacoeconomics|December 23, 2011
Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspectiveAurea Duran, Nishan Sengupta, Alexander Diamantopoulos, et al.
Thrombosis and Haemostasis|September 1, 2010
Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in CanadaAlexander Diamantopoulos, Michael Lees, Philip S Wells, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 21, 2004
Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UKMike Aristides, Michael Lees, Nick Botwood, et al.
Autophagy|December 11, 2012
IFNB1/interferon-β-induced autophagy in MCF-7 breast cancer cells counteracts its proapoptotic functionMalene Ambjørn, Patrick Ejlerskov, Yawei Liu, et al.
Journal of Medical Economics|April 13, 2012
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health PerspectiveHeather McDonald, Alex Diamantopoulos, Philip Wells, et al.
Health and Quality of Life Outcomes|December 2, 2008
Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitationAndrew Briggs, Diane Wild, Michael Lees, et al.
Lung Cancer (Amsterdam, Netherlands)|December 31, 2003
Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in EuropeJoan Schiller, Dominic Tilden, Michael Aristides, et al.
Population Health Metrics|November 28, 2018
The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictionsDavid Campbell, Ken O'Day, Nadine Hertel, et al.
Pageof 4